Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Hong Kong · Delayed Price · Currency is HKD

6.50

+0.25 (4.00%)

Jul 10, 2026, 10:24 AM HKT

-22.43% (1Y)

Market Cap	1.51B -38.5%
Revenue (ttm)	1.45B -4.6%
Net Income	154.02M -0.1%
EPS	0.63 -16.9%
Shares Out	241.52M
PE Ratio	9.96
Forward PE	n/a
Dividend	0.07 (1.06%)
Ex-Dividend Date	Jun 17, 2026

Volume	200
Open	6.50
Previous Close	6.25
Day's Range	6.50 - 6.50
52-Week Range	5.09 - 16.29
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About HKG:2566

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixin... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1993

Employees 1,794

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2566

Full Company Profile

Financial Performance

In 2025, HKG:2566's revenue was 1.31 billion, a decrease of -4.59% compared to the previous year's 1.37 billion. Earnings were 138.41 million, a decrease of -0.14%.

Financial numbers in CNY Financial Statements